These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36072876)

  • 41. Antithrombotic Therapy for Atrial Fibrillation and Coronary Disease Demystified.
    Andrade JG; Deyell MW; Wong GC; Macle L
    Can J Cardiol; 2018 Nov; 34(11):1426-1436. PubMed ID: 30404748
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial.
    Kerneis M; Gibson CM; Chi G; Mehran R; AlKhalfan F; Talib U; Pahlavani S; Mir M; Bode C; Halperin JL; Nafee T; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Fox KAA; Cohen M
    JACC Cardiovasc Interv; 2018 Apr; 11(7):626-634. PubMed ID: 29550085
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Non-Vitamin K Oral Anticoagulants (NOAC) Versus Vitamin K Antagonists (VKA) for Atrial Fibrillation with Elective or Urgent Percutaneous Coronary Intervention: A Meta-Analysis with a Particular Focus on Combination Type.
    Eyileten C; Postula M; Jakubik D; Toma A; Mirowska-Guzel D; Patti G; Renda G; Siller-Matula JM
    J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32295160
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Validation of the Academic Research Consortium for High Bleeding Risk criteria in Chinese patients with atrial fibrillation and acute coronary syndrome or undergoing percutaneous coronary intervention.
    Lyu SQ; Zhu J; Wang J; Wu S; Zhang H; Shao XH; Yang YM
    Thromb Res; 2022 Jan; 209():16-22. PubMed ID: 34844044
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial.
    Welsh RC; Dehghani P; Lopes R; Wojdyla DM; Aronson R; Granger CB; Windecker S; Vora AN; Vinereanu D; Halvorsen S; Parkhomenko A; Mehran R; Alexander JH; Goodman S
    Open Heart; 2022 Feb; 9(1):. PubMed ID: 35172988
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The feasibility and safety of "one-stop" left atrial appendage closure and percutaneous coronary intervention in atrial fibrillation patients with significant coronary artery disease (PCI-LAAC study).
    Wang Y; Wu D; Ma J; Liu X; Zhang H; So CY; Lam YY; Wang B; Wang J; Zhang H; Wang M; Song G; Wu Y
    Am J Cardiovasc Dis; 2021; 11(5):679-687. PubMed ID: 34849300
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting.
    Manzano-Fernández S; Pastor FJ; Marín F; Cambronero F; Caro C; Pascual-Figal DA; Garrido IP; Pinar E; Valdés M; Lip GYH
    Chest; 2008 Sep; 134(3):559-567. PubMed ID: 18641090
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial.
    Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM
    Circ Cardiovasc Interv; 2019 Nov; 12(11):e008160. PubMed ID: 31707805
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary Stents.
    Choi HI; Ahn JM; Kang SH; Lee PH; Kang SJ; Lee SW; Kim YH; Lee CW; Park SW; Park DW; Park SJ
    JACC Cardiovasc Interv; 2017 Jun; 10(11):1075-1085. PubMed ID: 28527773
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study.
    Lamberts M; Gislason GH; Lip GY; Lassen JF; Olesen JB; Mikkelsen AP; Sørensen R; Køber L; Torp-Pedersen C; Hansen ML
    Circulation; 2014 Apr; 129(15):1577-85. PubMed ID: 24470482
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antithrombotic therapy trends in non-valvular atrial fibrillation patients undergoing percutaneous coronary stent implantation: Results from a survey among fellows at the Japanese College of Cardiology.
    Fukamachi D; Hirayama A; Miyauchi K; Yasuda S; Ogawa H; Ito H; Daida H
    J Cardiol; 2018 Aug; 72(2):113-119. PubMed ID: 29599096
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Atrial fibrillation and coronary artery disease: a review on the optimal use of oral anticoagulants.
    Bocchino PP; Angelini F; Toso E
    Rev Cardiovasc Med; 2021 Sep; 22(3):635-648. PubMed ID: 34565066
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Contemporary Antithrombotic Treatment in Patients with Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Rationale and Design of the Greek AntiPlatElet Atrial Fibrillation (GRAPE-AF) Registry.
    Xanthopoulou I; Dragona VM; Davlouros P; Tsioufis C; Iliodromitis E; Alexopoulos D;
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):191-196. PubMed ID: 29679301
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Atrial fibrillation in acute coronary syndrome: patient characteristics and appropriate utilisation of anti-thrombotic therapy in New Zealand (ANZACS-QI 39).
    Ho CY; Nunn C; White J; Kerr A; Lee M
    N Z Med J; 2020 Jul; 133(1519):41-54. PubMed ID: 32777794
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Missed Opportunities to Initiate Oral Anticoagulant in Atrial Fibrillation: Insights from Australian Acute Coronary Syndrome Registries.
    Ma M; Hyun K; D'Souza M; Chew D; Brieger D
    Heart Lung Circ; 2021 Aug; 30(8):1157-1165. PubMed ID: 33642171
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dual antiplatelet therapy versus oral anticoagulation plus dual antiplatelet therapy in patients with atrial fibrillation and low-to-moderate thromboembolic risk undergoing coronary stenting: design of the MUSICA-2 randomized trial.
    Sambola A; Montoro JB; Del Blanco BG; Llavero N; Barrabés JA; Alfonso F; Bueno H; Cequier A; Serra A; Zueco J; Sabaté M; Rodríguez-Leor O; García-Dorado D
    Am Heart J; 2013 Oct; 166(4):669-75. PubMed ID: 24093846
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Atrial Fibrillation and Coronary Artery Disease: A Long-Term Perspective on the Need for Combined Antithrombotic Therapy.
    Fanaroff AC; Li S; Marquis-Gravel G; Giri J; Lopes RD; Piccini JP; Wang TY
    Circ Cardiovasc Interv; 2021 Dec; 14(12):e011232. PubMed ID: 34932388
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review.
    Capodanno D; Huber K; Mehran R; Lip GYH; Faxon DP; Granger CB; Vranckx P; Lopes RD; Montalescot G; Cannon CP; Ten Berg J; Gersh BJ; Bhatt DL; Angiolillo DJ
    J Am Coll Cardiol; 2019 Jul; 74(1):83-99. PubMed ID: 31272556
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Trends of Antithrombotic Treatment in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights from the GReek-AntiPlatElet Atrial Fibrillation (GRAPE-AF) Registry.
    Benetou DR; Varlamos C; Ktenas D; Tsiafoutis I; Koutouzis M; Bampali T; Mantis C; Zarifis J; Skalidis E; Aravantinos D; Varvarousis D; Lianos I; Kanakakis J; Pisimisis E; Ziakas A; Davlouros P; Alexopoulos D;
    Cardiovasc Drugs Ther; 2021 Feb; 35(1):11-20. PubMed ID: 33034806
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Temporal Trends of Antithrombotic Therapy in Patients With Acute Myocardial Infarction and Atrial Fibrillation: Insight From the KAMIR-NIH Registry.
    Lee OH; Kim Y; Cho DK; Kim JS; Kim BK; Choi D; Hong MK; Jeong MH; Jang Y;
    Front Cardiovasc Med; 2021; 8():762090. PubMed ID: 34901221
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.